Skip to content

Real-World Evidence Services

Generate robust evidence and insights by partnering with Flatiron's expert team of clinicians, scientists, and health data analysts.

Real-World-Evidence

Harness a decade of leadership in oncology real‑world evidence

For over a decade, Flatiron Health has been at the forefront of generating high-quality oncology real-world data. Now, you can leverage that expertise for all of your real-world evidence generation needs.

With our team of oncology clinicians, health data experts, and real-world data scientists, we generate robust evidence and insights with a flexible and fit-for-purpose approach to address growing oncology RWE needs—from early through late-stage development, commercialization, and post-market applications.

We know real-world data. We deliver oncology real-world evidence.

Building on over a decade of experience providing high-quality, oncology real-world data, Flatiron has expanded our real-world evidence (RWE) offerings to include analytic, scientific, and consultative services. Our in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your oncology portfolio.

Hear from Flatiron leaders on their vision for how integrated RWE solutions can help you maximize the value of RWD.

RWE Services Video Thumbnail
Flatiron_Website_02022023-75

Why data empathy really matters in oncology RWE

Having built the oncology RWD market from the ground up, Flatiron has unparalleled data empathy: a multi-faceted and deep understanding of oncology EHR data and its use in real-world evidence generation. Most oncology RWD is derived from unstructured physician notes rather than the structured patient data. Because we extract and curate data from our own oncology EHR systems, we understand the data lineage from beginning to end, including the nuances that are extremely important for drawing the correct conclusions from real-world data.

We're now expanding our offerings to leverage this expertise, providing end-to-end evidence solutions that start with the patient and culminate in the evidence.

The complete solution for generating impactful oncology real-world evidence

Flatiron's Integrated RWE Solutions offer a tailored approach to RWD/E generation, ensuring seamless collaboration across the oncology product lifecycle. By combining our industry-leading oncology data assets with our expert team of clinicians, scientists, and health data analysts, we deliver high-quality, actionable insights that drive better outcomes for patients.

Flatiron_WebsiteShots_02022023_Revised-7

Our in-house expertise is what sets us apart

60+

oncology clinicians

80+

quantitative scientists

150+

data engineers

11+

years exclusively in oncology

80+

publications co-authored with customers

30+

publications on RWE methodology

500+

publications featuring Flatiron Data

Flexible engagement models to suit your needs

We understand that each use case is unique, as are the needs of our partners. Flatiron offers a variety of ways to engage with our teams, including:

Augmenting your internal analytic team


We can provide expert support to your existing analytic team, offering specialized skills and knowledge in oncology RWE generation.

Executing a protocol-driven scientific project


Our expert team can lead and execute scientific projects based on specific protocols, ensuring accurate and timely delivery of results.

Providing "quick insights"


If you need rapid answers to critical questions, our team can generate actionable insights quickly to inform your decision-making process.

Delivering custom or syndicated data


We can provide customized data sets tailored to your project requirements or offer access to our syndicated oncology data assets.

USE CASES

Learn how our customers are using Flatiron real-world evidence in oncology

Discovery

Flatiron’s oncology real-world evidence solutions accelerate drug discovery by bridging the gap between genomics and clinical outcomes. Evaluating outcomes in specific populations improves the likelihood that you’ll discover the right drug targets in the right patient populations. Flatiron’s robust and trusted biomarker and treatment outcomes data are available for specific cancer types, including rare diseases, or across multiple tumors.

Get started today

Contact us now to learn more about our flexible, tailored solutions and how we can support your oncology evidence generation needs.